Silence Therapeutics (SLNCF) reported a net loss of $12.4 million, or $0.08 per basic and diluted share, for the third quarter ended September 30, 2026. Revenue was zero for the quarter, compared with $159,000 a year earlier.
Cash and cash equivalents totaled $247.7 million at September 30, including $201.3 million in gross proceeds from an August public offering. The company said its proposed acquisition by Merck KGaA, Darmstadt, Germany is expected to close in the first quarter of 2027, subject to customary closing conditions.
- R&D expenses fell to $9.3 million from $20.5 million in the prior-year quarter.
- G&A expenses declined to $4.9 million from $5.8 million.
- Total outstanding shares were 186.6 million as of September 30, 2026.
- Silence reported positive topline Phase 2 SANRECO results for divesiran in polycythemia vera.
